Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xvivo Perfusion AB's purchase of property, plant, equipment for the
three
months ended in Jun. 2026 was $0.00 Mil. It means Xvivo Perfusion AB spent $0.00 Mil on purchasing property, plant, equipment.
Xvivo Perfusion AB's purchase of property, plant, equipment for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00Mil.
Compared with last quarter ($0.00 Mil in Mar. 2026 ), Xvivo Perfusion AB spent the same money on purchasing property, plant, equipment in Jun. 2026 ($0.00 Mil).
Xvivo Perfusion AB Purchase Of Property, Plant, Equipment Related Terms
Xvivo Perfusion AB Purchase Of Property, Plant, Equipment Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Purchase Of Property, Plant, Equipment can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB Purchase Of Property, Plant, Equipment Chart
Xvivo Perfusion AB Purchase Of Property, Plant, Equipment Calculation
The amount used to purchase PPE.
Purchase Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Purchase Of Property, Plant, Equipment of $0.00 Mil mean?
Xvivo Perfusion AB (XVIPF) has a Purchase Of Property, Plant, Equipment of $0.00 Mil as of Jun. 2026. Purchase of PP&E is the total purchase of property, plant and equipment. View historical data for Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's Purchase Of Property, Plant, Equipment too high?
Xvivo Perfusion AB's current Purchase Of Property, Plant, Equipment is $0.00 Mil. Overall, Xvivo Perfusion AB has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Purchase Of Property, Plant, Equipment compare to ABT and SYK?
Xvivo Perfusion AB's Purchase Of Property, Plant, Equipment of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Purchase Of Property, Plant, Equipment for a Medical Devices & Instruments company?
A good Purchase Of Property, Plant, Equipment depends on the Medical Devices & Instruments industry context. However, Purchase Of Property, Plant, Equipment should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Purchase Of Property, Plant, Equipment mean?
A high Purchase Of Property, Plant, Equipment can signal that a stock is expensive relative to its fundamentals. Purchase of PP&E is the total purchase of property, plant and equipment. View historical data for Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Purchase Of Property, Plant, Equipment is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $45.29, compared to a current price of $30.95 — trading 31.7% below its estimated fair value. The current Purchase Of Property, Plant, Equipment is $0.00 Mil. Xvivo Perfusion AB's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Purchase Of Property, Plant, Equipment calculated?
Purchase Of Property, Plant, Equipment is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Purchase Of Property, Plant, Equipment is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $30.95 is trading 31.7% below its estimated GF Value™ of $45.29.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Purchase Of Property, Plant, Equipment: $0.00 Mil
GF Value™: $45.29 vs. price of $30.95 (31.7% below fair value)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
87GF Score
Get the complete analysis for XVIPF
Purchase Of Property, Plant, Equipment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
